GlassScriptPhysician profile
Tammy Jean Miller
NPI 1699981746
$2,867.16
in general payments reported to CMS, 2019-2025
34 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $252 · 2021: $456 · 2022: $452 · 2023: $452 · 2024: $425 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374 · Education: $16.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.27 |
| Education | $16.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $332.68 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $276.22 | 2019-2025 | Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $226.09 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $188.95 | 2019-2025 | Veltassa |
| Glaxosmithkline, LLC. | $163.58 | 2021-2024 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $152.29 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $149.19 | 2023-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $106.27 | 2019-2025 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $105.26 | 2021-2025 | |
| Akebia Therapeutics INC | $104.38 | 2019-2025 | Vafseo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $101.63 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $85.20 | 2021-2025 | Rayaldee |
| Kyowa Kirin, INC. | $85.17 | 2023-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $78.03 | 2024-2025 | |
| Baxter Healthcare | $77.92 | 2019-2024 | Renal - Chronic |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $72.73 | 2020-2023 | Ultomiris |
| Ardelyx, INC. | $61.42 | 2024-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $52.36 | 2021-2023 | Oxlumo |
| Ani Pharmaceuticals, INC. | $47.65 | 2022-2025 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $43.47 | 2023-2024 | Crysvita |
| Mallinckrodt Hospital Products INC. | $41.82 | 2024-2025 | Terlivaz |
| Medtronic, INC. | $37.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.49 | 2023-2024 | Gattex |
| Janssen Pharmaceuticals, INC | $31.63 | 2020 | |
| Horizon Therapeutics Plc | $30.05 | 2021-2023 | Krystexxa |
| Apellis Pharmaceuticals, INC. | $27.69 | 2025 | Empaveli |
| Nxstage Medical, INC. | $24.86 | 2019 | |
| Aurinia Pharma U.S., INC. | $22.61 | 2021 | |
| Biomerieux INC | $21.00 | 2023 | |
| Amag Pharmaceuticals, INC. | $20.61 | 2020 | |
| Daiichi Sankyo INC. | $19.12 | 2019 | |
| Genzyme Corporation | $18.36 | 2019 | |
| Lilly USA, LLC | $13.62 | 2024 | Jardiance |
| Avion Pharmaceuticals | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.